VARIOUS R/R PCNSL Treatment Options1,2
But No
Clear Choice

Many patients with PCNSL relapse after first-line treatment—and there are no FDA-approved therapies.1,2

Understanding R/R PCNSL

What are the challenges when navigating R/R PCNSL treatment?

Current Treatment Challenges

What are the barriers to advancement in R/R PCNSL treatment?

Future Outlook

*May include targeted agents, immunomodulatory agents, or other monotherapy/combination regimens.2

†Also a type of chemotherapy.

Not all drugs within the presented classes are used in the treatment of R/R PCNSL.

ASCT=autologous stem cell transplant; BTKi=Bruton tyrosine kinase inhibitor; FDA=Food and Drug Administration; IMiD=immunomodulatory drug; mAbs=monoclonal antibodies; R/R PCNSL=relapsing or refractory primary central nervous system lymphoma; WBRT=whole brain radiation therapy.

References: 1. Langner-Lemercier S, Houillier C, Soussain C, et al. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. Neuro Oncol. 2016;18(9):1297-1303. doi:10.1093/neuonc/now033 2. Ambady P, Doolittle ND, Fox CP. Relapsed and refractory primary CNS lymphoma: treatment approaches in routine practice. Ann Lymphoma. 2021;5:23. doi:10.21037/aol-21-20